Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Stintzing

Showing results (151-160 of 206) with videos related to

Pageof 21
Sort By:
European Radiology|August 17, 2022
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306Felix O Hofmann, Volker Heinemann, Melvin D'Anastasi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trialsAlessandra Raimondi, Federico Nichetti, Arndt Stahler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2025
Spatial tumor immune microenvironment as a prognostic and predictive biomarker in anti-EGFR-based maintenance for RAS wt metastatic CRC - the PanaMa (AIO KRK0212) trialAlexej Ballhausen, Susanna Swoboda, David Horst, et al.
Oncology Research and Treatment|April 2, 2024
Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114)Kathrin Heinrich, Volker Heinemann, Sebastian Stintzing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study groupNicolas Moosmann, Ludwig Fischer von Weikersthal, Ursula Vehling-Kaiser, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2017
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trialsMartin D Berger, Shinichi Yamauchi, Shu Cao, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2024
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)Dominik Paul Modest, Volker Heinemann, Philipp Schütt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal CancerDominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Anti-Cancer Drugs|June 6, 2017
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancerArndt Stahler, Volker Heinemann, Jens Neumann, et al.
The Pharmacogenomics Journal|June 22, 2018
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancerMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
Pageof 21

Showing results (151-160 of 206) with videos related to

Sort By:
Pageof 21
European Radiology|August 17, 2022
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306Felix O Hofmann, Volker Heinemann, Melvin D'Anastasi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trialsAlessandra Raimondi, Federico Nichetti, Arndt Stahler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2025
Spatial tumor immune microenvironment as a prognostic and predictive biomarker in anti-EGFR-based maintenance for RAS wt metastatic CRC - the PanaMa (AIO KRK0212) trialAlexej Ballhausen, Susanna Swoboda, David Horst, et al.
Oncology Research and Treatment|April 2, 2024
Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114)Kathrin Heinrich, Volker Heinemann, Sebastian Stintzing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study groupNicolas Moosmann, Ludwig Fischer von Weikersthal, Ursula Vehling-Kaiser, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2017
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trialsMartin D Berger, Shinichi Yamauchi, Shu Cao, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2024
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)Dominik Paul Modest, Volker Heinemann, Philipp Schütt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal CancerDominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Anti-Cancer Drugs|June 6, 2017
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancerArndt Stahler, Volker Heinemann, Jens Neumann, et al.
The Pharmacogenomics Journal|June 22, 2018
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancerMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
Pageof 21